- Home
- APLM vs APCX Comparison
APLM vs APCX Comparison
Compare APLM & APCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- APCX
- Stock Information
- Founded
- APLM 2016
- APCX 2006
- Country
- APLM United States
- APCX United States
- Employees
- APLM N/A
- APCX N/A
- Industry
- APLM Blank Checks
- APCX Finance: Consumer Services
- Sector
- APLM Finance
- APCX Finance
- Exchange
- APLM Nasdaq
- APCX Nasdaq
- Market Cap
- APLM 15.6M
- APCX N/A
- IPO Year
- APLM N/A
- APCX N/A
- Fundamental
- Price
- APLM $9.75
- APCX $0.60
- Analyst Decision
- APLM Strong Buy
- APCX
- Analyst Count
- APLM 2
- APCX 0
- Target Price
- APLM $425.00
- APCX N/A
- AVG Volume (30 Days)
- APLM 102.2K
- APCX 10.6M
- Earning Date
- APLM 02-15-2025
- APCX 11-14-2024
- Dividend Yield
- APLM N/A
- APCX N/A
- EPS Growth
- APLM N/A
- APCX N/A
- EPS
- APLM N/A
- APCX N/A
- Revenue
- APLM $2,101,000.00
- APCX $365,000.00
- Revenue This Year
- APLM N/A
- APCX $1,315.48
- Revenue Next Year
- APLM N/A
- APCX N/A
- P/E Ratio
- APLM N/A
- APCX N/A
- Revenue Growth
- APLM 70.54
- APCX N/A
- 52 Week Low
- APLM $6.50
- APCX $0.31
- 52 Week High
- APLM $105.00
- APCX $2.30
- Technical
- Relative Strength Index (RSI)
- APLM 50.39
- APCX 60.21
- Support Level
- APLM $7.23
- APCX $0.36
- Resistance Level
- APLM $8.88
- APCX $1.49
- Average True Range (ATR)
- APLM 1.37
- APCX 0.14
- MACD
- APLM 0.21
- APCX 0.02
- Stochastic Oscillator
- APLM 57.91
- APCX 24.32
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.